Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- Ann: Race releases complete cardio-protection data & video
Yes to an extent as the price that will ultimately be able to be...
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.70 |
Change
-0.140(7.61%) |
Mkt cap ! $289.4M |
Open | High | Low | Value | Volume |
$1.88 | $1.89 | $1.70 | $456.4K | 259.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $1.69 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 8662 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.690 |
2 | 6661 | 1.685 |
1 | 727 | 1.680 |
1 | 5970 | 1.675 |
1 | 727 | 1.670 |
Price($) | Vol. | No. |
---|---|---|
1.700 | 8662 | 1 |
1.730 | 943 | 1 |
1.740 | 500 | 1 |
1.745 | 727 | 1 |
1.755 | 727 | 1 |
Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |